Significant Payment Reform by CMS
Organogenesis Holdings Inc. (Nasdaq: ORGO), a prominent player in regenerative medicine based in Canton, Massachusetts, has expressed its appreciation for the recent payment reforms introduced by the Centers for Medicare & Medicaid Services (CMS). These reforms, focused on skin substitutes and cellular tissue-based products (CTPs), represent a crucial advancement for the company and the industry at large.
Positive Shift in Medical Payments
Gary S. Gillheeney, Sr., the President and CEO of Organogenesis, acknowledged the importance of this change, emphasizing how CMS has finalized the classifications established by the FDA. This includes a novel payment methodology applied in both physician offices and hospital outpatient settings. He stated, “We believe this new policy will increase access to PMA products while addressing abuse under the current system.”
Improving Access to Life-Saving Technologies
CMS’s new policy not only aims to increase access to important medical products but also recognizes the clinical distinctions between PMA products. Mr. Gillheeney highlighted that these steps taken by CMS could potentially lead to higher payments for these innovative products, thus expanding patient access. “We remain committed to working with CMS and other stakeholders to further expand access to these life-saving technologies,” he added.
Encouraging Innovation and Investment
The commitment from Organogenesis to collaborate with CMS and stakeholders is aimed at fostering investment and innovation in the regenerative medicine space. The company's goal is to ensure long-term market stability while making significant strides in product accessibility for patients requiring advanced wound care and surgical therapies.
Industry Leadership and Future Outlook
With over four decades of expertise in regenerative medicine, Organogenesis believes it is uniquely positioned for success within the skin substitutes market as we look toward 2026 and beyond. Mr. Gillheeney proudly stated, “With a diverse portfolio grounded in evidence-based technologies across all FDA categories, we are confident in our leadership position.”
Commitment to Patient Care
The company continues to prioritize patient care through the development of innovative wound care solutions. By working alongside CMS to reform payment processes, Organogenesis aims to improve the quality of care available to patients who rely on these essential therapies, ensuring they receive the necessary treatments promptly.
Frequently Asked Questions
What did Organogenesis praise about CMS's recent actions?
Organogenesis applauded CMS for its significant step in reforming payment structures for skin substitutes and tissue-based products, enhancing access and support for innovative treatments.
How does this reform affect patient care?
This reform is designed to improve access to PMA products, which are crucial for providing effective treatments in advanced wound care and surgical applications.
What is the stance of Organogenesis on future collaboration with CMS?
Organogenesis intends to work closely with CMS and other partners to further enhance access to regenerative medicine technologies and encourage ongoing innovation in the field.
What role does Organogenesis play in regenerative medicine?
As a leader in the regenerative medicine sector, Organogenesis develops, manufactures, and markets advanced wound care products and therapies for surgical and sports medicine markets.
How long has Organogenesis been in the regenerative medicine industry?
Organogenesis has over 40 years of experience in regenerative medicine, promoting advancements in the field and providing solutions to critical patient needs.
